Atopic Dermatitis

All children, but healthy controls, had a higher likelihood of behavioral issues. ADHD symptoms of attention, hyperactivity and impulse control, were higher in AD children. Quality of life lower in affected children.

In this article, Drs. Lawrence Eichenfield and Jessica Sprague review some of the most significant findings and developments in pediatric dermatology from the last year beginning with the availability of biologic agents for pediatric psoriasis and atopic dermatitis.

The first patient has been dosed in the phase two study of PR022 (hypochlorous acid, Realm Therapeutics), a topical gel treatment for patients with atopic dermatitis.

A small study finds that the combination of methotrexate and azathioprine is safe and effective as maintenance treatment for patients with moderate-to-severe atopic dermatitis for up to five years.

Moisturizers were described as the “cornerstone of therapy” in atopic dermatitis in the 2014 AAD guidelines for topical therapies in atopic dermatitis, but the products differ greatly by ingredients which can improve the condition or make it worse.

Adult AD may be influenced by childhood eczema, though most adults have no memory of childhood eczema.

Drug development for established atopic dermatitis focuses on both managing flares and long-term disease control.

Most moisturizes contain ingredients that are not advertised and could potentially harm some patients, study shows.

Adding caffeine to topical skin treatments would be a simple way to reduce inflammation in patients with atopic dermatitis and psoriasis, suggests a review presented at the Psoriasis: From Gene to Clinic International Congress, which took place in London this week.

In this slideshow, we summarize the phenotypes associated with childhood atopic dermatitis as addressed recently in JAMA Pediatrics.

The International Eczema Council (IEC) is recommending that the routine use of systemic corticosteroids for atopic dermatitis be discouraged and instead, it should be reserved for special circumstances.

A round-up of the latest products hitting the dermatology market including treatment for eczema and wounds, plus care for rejuvenating procedures.

Treatment for atopic dermatitis isn’t always straightforward. In this article, a physician outlines treatment approaches.

In this article, we take a look at the development of new treatments for atopic dermatitis.

“Because atopic dermatitis is episodic, its incidence, prevalence, persistence, remission, flare and long-term control require careful definition,” researchers write.

New recommendations from the International Eczema Council aim to address a question that has gone largely unanswered: When should dermatologists and others prescribe systemic therapy to treat atopic dermatitis?

Atopic dermatitis patients have a phobia of topical corticosteroids that is so strong, it’s been described as a “phenomenon.”

A pilot study shows that Manuka honey may have some healing properties in atopic dermatitis.

Children under two years old with signs of atopic dermatitis have an increased risk of developing asthma and food allergies, researchers report in JAMA Pediatrics. And, young children with both early onset atopic dermatitis and a food allergy, have a “very high risk” of developing asthma or allergic rhinitis.

Patch testing for allergic contact dermatitis in the pediatric population is performed at a higher rate than previously reported, but still grossly underreported, according to a study of the Pediatric Contact Dermatitis Registry.

In this slideshow, we highlight four atopic dermatitis phenotypes in children as described in JAMA Pediatrics.

EADV study shows that this JAK inhibitor is a promising drug candidate in moderate-to-severe AD.

Ingredients used in topical products used to relieve atopic dermatitis in children might put those patients at higher risk for contact dermatitis.

NIH investigators find that Staphylococcus epidermidis is predominant in less severe cases, while Staphylococcus aureus is associated with patients who have more severe disease.

Nitric oxide-releasing cream that targets IL-17 moving toward clinical trials.

An experimental drug designed to control itching in people with moderate-to-severe AD shows promise in early trial.

A new study shows that mutations in the gene CARD11 are associated with severe atopic disease.

In early research, subcutaneous nemolizumab significantly reduced pruritus in moderate-to-severe atopic dermatitis adult patients.

Patients with severe atopic dermatitis who have lower serum vitamin D levels have a high sensitivity to house dust mites which can aggravate their condition, a new study shows.

Long-term data for dupilumab in atopic dermatitis revealed at the American Academy of Dermatology (AAD) 75th Annual Meeting reflect safety, rapid relief of troublesome symptoms and a long-lived response in keeping with the drug’s breakthrough status, experts told Dermatology Times.